South Africa Cell And Gene Therapy Clinical Trials Market Size & Outlook
South Africa cell and gene therapy clinical trials market, 2018-2030 (US$M)
Related Markets
South Africa cell and gene therapy clinical trials market highlights
- The South Africa cell and gene therapy clinical trials market generated a revenue of USD 134.3 million in 2023 and is expected to reach USD 235.5 million by 2030.
- The South Africa market is expected to grow at a CAGR of 8.4% from 2024 to 2030.
- In terms of segment, phase ii was the largest revenue generating phase in 2023.
- Phase II is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy clinical trials market data book summary
| Market revenue in 2023 | USD 134.3 million |
| Market revenue in 2030 | USD 235.5 million |
| Growth rate | 8.4% (CAGR from 2023 to 2030) |
| Largest segment | Phase ii |
| Fastest growing segment | Phase II |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
Other key industry trends
- In terms of revenue, South Africa accounted for 1.4% of the global cell and gene therapy clinical trials market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa cell and gene therapy clinical trials market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 235.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy Clinical Trials Market Scope
Cell And Gene Therapy Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Africa cell and gene therapy clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 55.4% in 2023. Horizon Databook has segmented the South Africa cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
The South African market is expected to witness growth owing to presence of well-established infrastructure, diverse population, availability of experts, formation of separate drug regulatory agency, and easy patient recruitment. South Africa was once a commonly considered country for clinical research, but its popularity generated bottlenecks in the country's previously built regulatory structure.
Biotechnology and pharmaceutical corporations began pressuring for reform and actively lobbied the South African government. Their efforts compelled the Minister of Health to take initiatives. The South African government overhauled its whole regulatory environment, establishing SAHPRA to oversee clinical trial evaluation and approval as well as medicinal approvals Cell and gene therapy clinical trials are outsourced to South Africa as a result of easy availability of subjects as a large number of people are suffering from HIV/AIDS.
There are around 5.6 million people in Africa suffering from HIV out of which only 2.5 million have access to drugs. There are more than 2000 cell and gene therapy clinical trials registered on ClinicalTrails.gov. The majority of the registered trials are for HIV and Tuberculosis. This has accelerated outsourcing to South Africa by international players.
Reasons to subscribe to South Africa cell and gene therapy clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Africa cell and gene therapy clinical trials market databook
-
Our clientele includes a mix of cell and gene therapy clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into South Africa cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
South Africa cell and gene therapy clinical trials market size, by phase, 2018-2030 (US$M)
South Africa Cell And Gene Therapy Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
